----
Current ValuationThe current P/E ratio is 65.97, above the reasonable range, cheaper than 4.98% of the time in the past 1 years, and the industry ranks 53/255, the industry Median -1.12.
65.97xP/E
$39.97Stock price
$0.61Earnings per share
65.97xP/E
Stock price$39.97Earnings per share$0.61
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- 28.38x
- Typical range
- 25.01x–60.01x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
0285684112
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
| Name/Symbol | |||
|---|---|---|---|
TEVAUSTeva Pharmaceutical Industries | 65.97x | 61.46% | $46.58B |
SDZNYUSSANDOZ GROUP AG SPON ADS EACH REP 1 COM SHS | 64.30x | -- | $41.54B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
